What are the diagnostic criteria for neuroleptic (antipsychotic) malignant syndrome (NMS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria for Neuroleptic Malignant Syndrome

The diagnosis of NMS requires a point-based scoring system where ≥76 points indicates probable NMS, incorporating dopamine antagonist exposure, hyperthermia, rigidity, mental status changes, elevated creatine kinase, autonomic instability, hypermetabolism, and exclusion of other causes. 1

Point-Based Diagnostic Scoring System

The American Academy of Pediatrics recommends the following point allocation for NMS diagnosis:

  • Dopamine antagonist exposure or dopamine agonist withdrawal within 3 days: 20 points 1
  • Hyperthermia (>100.4°F oral on ≥2 occasions): 18 points 1
  • Rigidity: 17 points 1
  • Mental status alteration: 13 points 1
  • Creatine kinase elevation (≥4 times upper limit of normal): 10 points 1
  • Sympathetic nervous system lability: 10 points 1
  • Hypermetabolism: 5 points 1
  • Negative workup for infectious, toxic, metabolic, or neurologic causes: 7 points 1

Core Clinical Features (The Classic Tetrad)

Mental Status Changes

Delirium is the most common mental status presentation, ranging from alert mutism to agitation to stupor to coma. 1 Mental status changes or rigidity are the initial manifestations in 82.3% of cases. 2

Muscle Rigidity

"Lead pipe" rigidity is the most common neurologic finding, though other muscle abnormalities including akinesia, dyskinesia, or waxy flexibility may occur. 1 This rigidity is distinct from the hyperreflexia and clonus seen in serotonin syndrome. 3

Hyperthermia

Fever progressing to hyperthermia (temperatures up to 41.1°C or higher) is a hallmark feature. 1, 4 The hyperthermia results from dopamine D2 receptor blockade in the hypothalamus, which increases the temperature set point and impairs heat-dissipating mechanisms. 4

Autonomic Instability

Tachycardia and blood pressure fluctuations are common autonomic dysfunction symptoms, often preceding other symptoms. 1 Additional autonomic features include diaphoresis, sialorrhea, and dysphagia. 1

Temporal Progression of Symptoms

Mental status changes or rigidity typically appear first, followed by hyperthermia, then autonomic dysfunction. 2 This sequence occurs in 70.5% of cases, making early recognition of mental status changes and rigidity critical for prompt intervention. 2

Laboratory Findings

Essential Laboratory Abnormalities

  • Elevated creatine kinase (≥4 times upper limit of normal) is a key diagnostic criterion, resulting from muscle breakdown due to sustained rigidity. 1, 4
  • Leukocytosis (15,000-30,000 cells/mm³) commonly accompanies NMS. 1, 4
  • Electrolyte abnormalities consistent with dehydration are frequently observed. 1, 4
  • Elevated liver enzymes may be present due to systemic stress. 1, 4

Important Caveat

While elevated CPK is included in diagnostic criteria, rare atypical presentations with normal or minimally elevated CPK have been reported, though these cases still met other diagnostic criteria. 5 Do not exclude NMS solely based on normal CPK if other features are present.

Critical Differential Diagnoses to Exclude

Serotonin Syndrome

Distinguished by hyperreflexia, clonus, and myoclonus rather than lead-pipe rigidity, with recent serotonergic drug exposure and more rapid onset (minutes to hours versus days). 3, 1 Serotonin syndrome patients have increased muscle tone predominantly in lower extremities, while NMS shows generalized lead-pipe rigidity. 3

Malignant Hyperthermia

Triggered by inhalational anesthetics with or without succinylcholine, not antipsychotics, with onset typically within 12 hours of anesthetic exposure and rigor mortis-like rigidity. 3, 1

Anticholinergic Toxicity

Presents with hot, dry skin and mydriasis, contrasting with the diaphoresis and sialorrhea of NMS. 3, 1 Mental status is agitated delirium in both, but anticholinergic toxicity lacks rigidity. 3

CNS Infections and Acute Catatonia

Meningitis, encephalitis, and catatonic syndrome must be excluded through appropriate workup including lumbar puncture if indicated. 1

Clinical Context and Risk Factors

Medication History

History of antipsychotic use (typical or atypical) or withdrawal of dopaminergic agents within 3 days is essential. 1 NMS typically develops within 1-7 days of exposure. 3

Additional Risk Factors

  • Coadministration of multiple psychotropic agents 1
  • Dehydration and physical exhaustion 1
  • Preexisting organic brain disease 1
  • Use of long-acting depot antipsychotics 1
  • Male gender (2:1 male predominance) 1

Diagnostic Pitfalls

NMS can present with variable and attenuated presentations, making recognition challenging. 1 The diagnosis is entirely clinical, as there are no pathognomonic laboratory or radiographic findings. 1 However, early recognition is crucial, as mortality has decreased from 76% in the 1960s to <10-15% with prompt management. 1, 4

The syndrome lasts 7-10 days in uncomplicated cases receiving oral neuroleptics, though duration may be prolonged with depot formulations. 6

References

Guideline

Neuroleptic Malignant Syndrome (NMS) Clinical Presentation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Progression of symptoms in neuroleptic malignant syndrome.

The Journal of nervous and mental disease, 1994

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Neuroleptic Malignant Syndrome Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Neuroleptic Malignant Syndrome with Normal Creatine Phosphokinase Levels: An Atypical Presentation.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2022

Research

Neuroleptic malignant syndrome.

The Medical clinics of North America, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.